- Home
- NVNO vs NERV Comparison
NVNO vs NERV Comparison
Compare NVNO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- NERV
- Stock Information
- Founded
- NVNO 1987
- NERV 2007
- Country
- NVNO United States
- NERV United States
- Employees
- NVNO N/A
- NERV N/A
- Industry
- NVNO Medical/Dental Instruments
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- NVNO Health Care
- NERV Health Care
- Exchange
- NVNO Nasdaq
- NERV Nasdaq
- Market Cap
- NVNO 16.7M
- NERV 14.6M
- IPO Year
- NVNO N/A
- NERV 2014
- Fundamental
- Price
- NVNO $0.71
- NERV $4.60
- Analyst Decision
- NVNO
- NERV Hold
- Analyst Count
- NVNO 0
- NERV 1
- Target Price
- NVNO N/A
- NERV $5.00
- AVG Volume (30 Days)
- NVNO 331.1K
- NERV 9.3M
- Earning Date
- NVNO 10-31-2025
- NERV 11-05-2025
- Dividend Yield
- NVNO N/A
- NERV N/A
- EPS Growth
- NVNO N/A
- NERV N/A
- EPS
- NVNO N/A
- NERV 1.48
- Revenue
- NVNO N/A
- NERV N/A
- Revenue This Year
- NVNO N/A
- NERV N/A
- Revenue Next Year
- NVNO N/A
- NERV N/A
- P/E Ratio
- NVNO N/A
- NERV $3.06
- Revenue Growth
- NVNO N/A
- NERV N/A
- 52 Week Low
- NVNO $0.67
- NERV $1.15
- 52 Week High
- NVNO $5.62
- NERV $12.46
- Technical
- Relative Strength Index (RSI)
- NVNO 32.52
- NERV 62.59
- Support Level
- NVNO $0.68
- NERV $4.27
- Resistance Level
- NVNO $0.76
- NERV $12.46
- Average True Range (ATR)
- NVNO 0.06
- NERV 0.84
- MACD
- NVNO 0.03
- NERV 0.19
- Stochastic Oscillator
- NVNO 16.45
- NERV 23.11
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.